NURTEC ODT Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Nurtec Odt, and what generic alternatives are available?
Nurtec Odt is a drug marketed by Biohaven Ireland and is included in one NDA. There are three patents protecting this drug.
This drug has one hundred and three patent family members in thirty-five countries.
The generic ingredient in NURTEC ODT is rimegepant sulfate. One supplier is listed for this compound. Additional details are available on the rimegepant sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Nurtec Odt
Nurtec Odt will be eligible for patent challenges on February 27, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 25, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NURTEC ODT
International Patents: | 103 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 2 |
Patent Applications: | 1 |
Drug Prices: | Drug price information for NURTEC ODT |
What excipients (inactive ingredients) are in NURTEC ODT? | NURTEC ODT excipients list |
DailyMed Link: | NURTEC ODT at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NURTEC ODT
Generic Entry Date for NURTEC ODT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NURTEC ODT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Antonios Likourezos | Phase 4 |
Weill Medical College of Cornell University | Phase 2 |
Biohaven Pharmaceuticals, Inc. | Phase 2 |
Pharmacology for NURTEC ODT
Drug Class | Calcitonin Gene-related Peptide Receptor Antagonist |
Mechanism of Action | Calcitonin Gene-related Peptide Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for NURTEC ODT
US Patents and Regulatory Information for NURTEC ODT
NURTEC ODT is protected by five US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NURTEC ODT is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting NURTEC ODT
Rimegepant for CGRP related disorders
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Rimegepant for CGRP related disorders
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
CGRP receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
CGRP receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting NURTEC ODT
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biohaven Ireland | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Biohaven Ireland | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Biohaven Ireland | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Biohaven Ireland | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Biohaven Ireland | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NURTEC ODT
When does loss-of-exclusivity occur for NURTEC ODT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13226361
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2014021032
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 65585
Estimated Expiration: ⤷ Try a Trial
China
Patent: 4136437
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0171620
Estimated Expiration: ⤷ Try a Trial
Patent: 0191655
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 19448
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 20016
Estimated Expiration: ⤷ Try a Trial
Patent: 54681
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 5358
Estimated Expiration: ⤷ Try a Trial
Patent: 1491585
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 20016
Estimated Expiration: ⤷ Try a Trial
Patent: 54681
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 48111
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 34936
Estimated Expiration: ⤷ Try a Trial
Patent: 47050
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 4272
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 08154
Estimated Expiration: ⤷ Try a Trial
Patent: 76253
Estimated Expiration: ⤷ Try a Trial
Patent: 15511581
Estimated Expiration: ⤷ Try a Trial
Patent: 17226693
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 20016
Estimated Expiration: ⤷ Try a Trial
Patent: 54681
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 2171
Estimated Expiration: ⤷ Try a Trial
Patent: 14009544
Estimated Expiration: ⤷ Try a Trial
Norway
Patent: 35439
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 20016
Estimated Expiration: ⤷ Try a Trial
Patent: 54681
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 20016
Estimated Expiration: ⤷ Try a Trial
Patent: 54681
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 556
Estimated Expiration: ⤷ Try a Trial
Patent: 295
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201404834X
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 20016
Estimated Expiration: ⤷ Try a Trial
Patent: 54681
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 2076118
Estimated Expiration: ⤷ Try a Trial
Patent: 2220969
Estimated Expiration: ⤷ Try a Trial
Patent: 140130140
Estimated Expiration: ⤷ Try a Trial
Patent: 200016993
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 42737
Estimated Expiration: ⤷ Try a Trial
Patent: 46031
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering NURTEC ODT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | S2200033 | ⤷ Try a Trial | |
Serbia | 53149 | ANTAGONISTI RECEPTORA ZA CGRP (CGRP RECEPTOR ANTAGONISTS) | ⤷ Try a Trial |
Japan | 6208154 | ⤷ Try a Trial | |
Slovenia | 2488512 | ⤷ Try a Trial | |
South Korea | 20120087940 | CGRP RECEPTOR ANTAGONISTS | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NURTEC ODT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2488512 | 2022C/540 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RIMEGEPANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1645 20220426 |
2488512 | PA2022516 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: RIMEGEPANTAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/22/1645 20220425 |
2488512 | LUC00272 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: RIMEGEPANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/22/1645 20220426 |
2488512 | 301187 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: RIMEGEPANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/22/1645 20220426 |
2488512 | 33/2022 | Austria | ⤷ Try a Trial | PRODUCT NAME: RIMEGEPANT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1645 (MITTEILUNG) 20220426 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |